Jiangsu Nhwa Pharmaceutical Co., LTD (SHE:002262)

Market Cap	19.71B -12.4%
Revenue (ttm)	6.01B +2.7%
Net Income	1.07B -8.9%
EPS	1.06 -9.3%
Shares Out	1.02B
PE Ratio	18.29
Forward PE	15.28
Dividend	0.40 (2.07%)
Ex-Dividend Date	May 26, 2026

Volume	7,488,936
Open	19.53
Previous Close	19.40
Day's Range	19.01 - 19.62
52-Week Range	18.71 - 29.30
Beta	-0.21
Analysts	Buy
Price Target	26.70 (+39.5%)
Earnings Date	Jul 30, 2026

About SHE:002262

Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases. Its products include sufentanil citrate injection, oxaliplatin fumarate injection, alfentanil hydrochloride injection, oxycodone hydrochloride injection, olanzapine tablets, midazolam hydrochloride oral solution, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 6,003
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002262

Financial Performance

In 2025, SHE:002262's revenue was 5.91 billion, an increase of 3.75% compared to the previous year's 5.70 billion. Earnings were 1.06 billion, a decrease of -7.54%.

Analyst Summary

According to 4 analysts, the average rating for 002262 stock is "Buy." The 12-month stock price target is ¥26.70, which is an increase of 39.50% from the latest price.

Price Target

¥26.70

(39.50% upside)

Analyst Consensus: Buy